期刊
MOLECULAR PHARMACEUTICS
卷 11, 期 4, 页码 1081-1093出版社
AMER CHEMICAL SOC
DOI: 10.1021/mp400680d
关键词
peptides; brain delivery; blood brain barrier; opioid peptides; neurodegenerative diseases; intravenous; oral; intranasal; receptor-mediated endocytosis; nanoparticles; cell penetrating peptides
资金
- Engineering and Physical Sciences Research Council [GR/T20410/02, EP/K502340/1, GR/T20410/01, EP/L024748/1, EP/G061483/1] Funding Source: researchfish
- EPSRC [EP/K502340/1, EP/L024748/1, EP/G061483/1] Funding Source: UKRI
Neurological diseases such as neurodegeneration, pain, psychiatric disorders, stroke, and brain cancers would greatly benefit from the use of highly potent and specific peptide pharmaceuticals. Peptides are especially desirable because of their low inherent toxicity. The presence of the blood brain barrier (BBB), their short duration of action, and their need for parenteral administration limits their clinical use. However, over the past decade there have been significant advances in delivering peptides to the central nervous system. Angiopep peptides developed by Angiochem (Montreal, Canada), transferrin antibodies developed by ArmaGen (Santa Monica, USA), and cell penetrating peptides have all shown promise in delivering therapeutic peptides across the BBB after intravenous administration. Noninvasive methods of delivering peptides to the brain include the use of chitosan amphiphile nanoparticles for oral delivery and nose to brain strategies. The uptake of the chitosan amphiphile nanoparticles by the gastrointestinal epithelium is important for oral peptide delivery. Finally protecting peptides from plasma degradation is integral to delivery strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据